tiprankstipranks
Trending News
More News >

Terns Pharmaceuticals Appoints Robert Azelby to Board

Story Highlights
Terns Pharmaceuticals Appoints Robert Azelby to Board

Confident Investing Starts Here:

Terns Pharmaceuticals ( (TERN) ) has shared an announcement.

On February 20, 2025, Carl Gordon resigned from the Board of Directors of Terns Pharmaceuticals, and Robert Azelby was appointed as a new member and a part of the Compensation Committee. Mr. Azelby, a seasoned executive with extensive experience in the biopharmaceutical industry, is expected to bring strategic and operational expertise, particularly in advancing Terns’ oncology programs, such as TERN-701 for chronic myeloid leukemia, into late-stage studies.

More about Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases such as oncology and obesity. The company’s portfolio includes several clinical stage development programs, such as an allosteric BCR-ABL inhibitor and a GLP-1 receptor agonist.

YTD Price Performance: -26.10%

Average Trading Volume: 1,817,446

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $350.8M

Learn more about TERN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App